Dr. Christian Meisel, MD PhD, is a highly accomplished academic physician scientist with substantial contributions to the field of medicine and innovation in drug development. He holds board certifications in Internal Medicine and Clinical Pharmacology from the esteemed Charité University Hospital and has an additional background in Informatics. Dr. Meisel is renowned as a thought leader in Precision Oncology, where he played a central role in advancing drug development and clinical diagnostics. His passion and devotion to this field have earned him widespread recognition and acclaim. Prior to cofounding Hedera Dx and assuming the role of Chief Medical Officer, Dr. Meisel had a distinguished career in the biopharmaceutical industry. He held key global leadership positions at Roche, including Global Head Translational Medicine Oncology, Oncology Biomarkers, and Personalized Healthcare Platforms. Additionally, his role as Chief Medical Officer at Molecular Health bolstered his leadership and expertise in patientcentric precision medicine and clinical decision support.
Hedera Dx: Transforming oncology through liquid biopsy
Liquid Biopsy has the potential to transform Oncology. Hedera Dx pioneers noninvasive liquid biopsy solutions, reshaping oncology and significantly enhancing patient outcomes through better diagnostics for more patients as well as by accelerating and improving drug development through patientcentricity and clinicogenomics realworld evidence generation.
Clinical Dx Showcase:
Hedera Dx is on a mission to improve patient outcomes by simplifying clinical cancer testing and providing an unprecedented platform for cancer drug development
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative